Pharnext esPharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Biotechnology

Pharnext

Pharnext's headquarters in Issy-les-Moulineaux, France

Hugo Brugière

Vincent Serra

Kévin Scialom

Gilbert Wagener

Serguei Nabirotchkine, PhD

Raj Thota

Leadership Team

Clinical Operations and Development

Pharnext

Org chart

Teams

Leadership Team

Clinical Operations and Development

Offices

Similar companies